×
About 888 results

ALLMedicine™ Anaplastic Astrocytoma Center

Research & Reviews  291 results

Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients
https://clinicaltrials.gov/ct2/show/NCT02796261

Jan 14th, 2022 - This study will consist of 4 study periods of up to 50 months in total, consisting of: Screening Period - A maximum screening duration of 4 weeks. Treatment Period - Treatment Arm A up to 24 months; Treatment Arm B up to 12 months. End of Treatmen...

Hormone exposure and its suppressive effect on risk of high-grade gliomas among patient...
https://doi.org/10.1016/j.jocn.2021.10.029
Journal of Clinical Neuroscience : Official Journal of Th... Lopez-Garcia CA, Lopez-Rivera V et. al.

Dec 6th, 2021 - Prior reports demonstrate the expression of estrogen and progesterone receptors in high-grade gliomas (HGGs), but the relationship between hormone receptor-positive disease and risk of HHGs in patients with breast cancer (BC) remains uncharacteriz...

Related expression of TRKA and P75 receptors and the changing copy number of MYC-oncoge...
https://doi.org/10.1515/dmpt-2020-0109
Drug Metabolism and Personalized Therapy; Chernov AN, Alaverdian DA et. al.

Oct 28th, 2021 - Oncological diseases are an urgent medical and social problem. The chemotherapy induces not only the death of the tumor cells but also contributes to the development of their multidrug resistance and death of the healthy cells and tissues. In this...

Temozolomide Rechallenge in Patients With Recurrent High-Grade Glioma Treated With Re-I...
https://doi.org/10.1016/j.ijrobp.2021.07.1574
International Journal of Radiation Oncology, Biology, Phy... Basree MM, Ali A et. al.

Oct 28th, 2021 - To evaluate the clinical role of temozolomide rechallenge (TMZ) in patients with recurrent high-grade glioma (HGG) treated with re-irradiation (re-RT) regardless of surgical status. Single-center retrospective review of patients with a primary dia...

Identification of De Novo Pyrimidine Synthesis as a Targetable Vulnerability in a Novel...
https://doi.org/10.1016/j.ijrobp.2021.07.205
International Journal of Radiation Oncology, Biology, Phy... Shi DD, Wang AC et. al.

Oct 28th, 2021 - Despite high prevalence of IDH1-R132H mutations in grade II-III gliomas, effective therapies remain limited. We sought to identify tumor-specific vulnerabilities induced by the IDH1-R132H oncogene and test the translational relevance of targeting ...

see more →

Drugs  15 results see all →

Clinicaltrials.gov  33 results

Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients
https://clinicaltrials.gov/ct2/show/NCT02796261

Jan 14th, 2022 - This study will consist of 4 study periods of up to 50 months in total, consisting of: Screening Period - A maximum screening duration of 4 weeks. Treatment Period - Treatment Arm A up to 24 months; Treatment Arm B up to 12 months. End of Treatmen...

Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma
https://clinicaltrials.gov/ct2/show/NCT01386710

Oct 28th, 2021 - The high-grade malignant brain tumors, glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA), comprise the majority of all primary brain tumors in adults. This group of tumors also exhibits the most aggressive behavior, resulting in median...

Study of Convection-Enhanced, Image-Assisted Delivery of Liposomal-Irinotecan In Recurrent High Grade Glioma
https://clinicaltrials.gov/ct2/show/NCT02022644

Oct 27th, 2021 - High grade gliomas (HGG) are the most common brain tumor in adults, with 15,000 new cases/year in the USA. Despite progress made using combination therapies including surgery, radiation and/or chemotherapy, the treatment of HGG remains challenging...

Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors
https://clinicaltrials.gov/ct2/show/NCT02644291

Sep 21st, 2021 - The primary objectives of this study are to determine the maximum tolerated dose (MTD) of oral mebendazole in patients with recurrent/progressive pediatric brain tumors and to confirm the tolerance of the MTD of oral mebendazole by assessing toler...

BPM31510 in Treating Patients With Recurrent High-Grade Glioma Previously Treated With Bevacizumab
https://clinicaltrials.gov/ct2/show/NCT03020602

Aug 10th, 2021 - Primary Objective: Assess the safety and tolerability of BPM31510 plus vitamin K in subjects with high-grade glioma(HGG), defined as anaplastic astrocytoma (AA) or glioblastoma (GB) that has recurred on a BEV containing regimen. Secondary Objectiv...

see more →

News  16 results

Toca 511 Shows Promise in High-Grade Glioma
https://www.onclive.com/view/toca-511-shows-promise-in-highgrade-glioma

Dec 20th, 2020 - Timothy Cloughesy, MD The gene for an anticancer drug was successfully transduced in high-grade gliomas, according to data from a phase I trial of Toca 511 presented at the 2016 Society for Neuro-Oncology Annual Meeting. Additionally, the median ...

5 Abstracts Offer Snapshot of Immunology Research
https://www.onclive.com/view/5-abstracts-offer-snapshot-of-immunology-research

Dec 5th, 2020 - The carcinoembryonic antigen (CEA) vaccinia has been researched for more than 20 years. Investigational Glioma Vaccine Results Promising A novel vaccine based on dendritic cells and peptides proved to be safe and capable of delivering an im...

New Era of CDK Targeting Gets Rolling in Oncology
https://www.onclive.com/view/new-era-of-cdk-targeting-gets-rolling-in-oncology

Dec 5th, 2020 - In the oncology sphere, 2 members of the cyclin-dependent kinase (CDK) family have long stood out from the crowd. Serving as gatekeepers at the entry to the cell cycle, CDK4 and CDK6 make ideal therapeutic targets to block the unchecked proliferat...

Investigators Hope Glioma Trial of Eflornithine Will Clinch Approval
https://www.onclive.com/view/investigators-hope-glioma-trial-of-eflornithine-will-clinch-approval

Dec 5th, 2020 - Victor A. Levin, MD Eflornithine (α-Difluoromethylornithine) has been investigated for over 30 years as a potential neuro-oncology agent and shown activity against recurrent gliomas, but it has not gained approval as a therapy option for patients...

Oncolytic Viruses Primed for Growth
https://www.onclive.com/view/oncolytic-viruses-primed-for-growth

Dec 5th, 2020 - Robert Andtbacka, MD Amid the rapid expansion of immunotherapy for a wide range of tumor types, oncolytic virus therapies are generating growing attention from researchers and pharmaceutical developers, raising the potential for a new class of im...

see more →